Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Short Interest Down 69.8% in June

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) was the target of a significant drop in short interest in the month of June. As of June 30th, there was short interest totaling 26,939 shares, a drop of 69.8% from the June 15th total of 89,259 shares. Based on an average trading volume of 337,966 shares, the short-interest ratio is currently 0.1 days. Approximately 1.7% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Scinai Immunotherapeutics Price Performance

NASDAQ SCNI traded down $0.01 on Friday, reaching $0.25. The company had a trading volume of 37,699 shares, compared to its average volume of 386,794. The stock has a market capitalization of $992,772.00, a PE ratio of -0.24 and a beta of 2.11. Scinai Immunotherapeutics has a 12 month low of $0.24 and a 12 month high of $3.48. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.05. The firm’s 50 day moving average price is $0.40 and its 200 day moving average price is $0.63.

Scinai Immunotherapeutics (NASDAQ:SCNI) last issued its quarterly earnings data on Wednesday, April 1st. The company reported $3.80 earnings per share for the quarter. The firm had revenue of $0.27 million for the quarter.

Institutional Trading of Scinai Immunotherapeutics

A hedge fund recently raised its position in Scinai Immunotherapeutics stock. Citadel Advisors LLC grew its position in shares of Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% in the third quarter, according to its most recent filing with the SEC. The fund owned 28,630 shares of the company’s stock after acquiring an additional 17,031 shares during the quarter. Citadel Advisors LLC owned about 0.90% of Scinai Immunotherapeutics worth $36,000 at the end of the most recent reporting period. 58.41% of the stock is owned by institutional investors.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.